NGL Fine-Chem Limited

NSE NGLFINE.NS

NGL Fine-Chem Limited Free Cash Flow Yield on January 31, 2025: -0.82%

NGL Fine-Chem Limited Free Cash Flow Yield is -0.82% on January 31, 2025, a -346.71% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

NGL Fine-Chem Limited 52-week high Free Cash Flow Yield is 0.35% on February 13, 2024, which is 142.72% above the current Free Cash Flow Yield.
NGL Fine-Chem Limited 52-week low Free Cash Flow Yield is -0.82% on January 31, 2025, which is 0.00% below the current Free Cash Flow Yield.
NGL Fine-Chem Limited average Free Cash Flow Yield for the last 52 weeks is -0.47%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NSE: NGLFINE.NS

NGL Fine-Chem Limited

CEO	Mr. Rahul Jayant Nachane
IPO Date	July 8, 2022
Location	India
Headquarters	301, E Square
Employees	682
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Key trends

Past 5 years